Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

PASI (used in Phase 2b) and IGA scoring (used in Phase 2a) are different beasts, but they are correlated. I know the board talked a lot about going back and forth between the two psoriasis severity scales in the past, including one of my takes:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132378987

To answer your first question: yes, I think that PASI - 75% reduction is probably easier to meet than IGA>=2 point drop.

Second question: no. I have stated before (in post to which you responded here) and agree with NR that the Phase 2a trial did NOT show statistically significant differences in 200 mg group vs. placebo. From memory, I believe the P value was ~0.2, which would mean there was a ~20% chance there was really no difference between prurisol and placebo. Having nothing else to go on, I estimated that was the odds of failure in Phase 2b trial, 15-20%.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132380775